Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 October 2005, Vol. 106, No. 7, pp. 2424-2432.
Prepublished online as a Blood First Edition Paper on June 23, 2005; DOI 10.1182/blood-2005-01-0342.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
2005-01-0342v1
106/7/2424    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gunzer, M.
Right arrow Articles by Grabbe, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gunzer, M.
Right arrow Articles by Grabbe, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted January 25, 2005
Accepted June 3, 2005

Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral blood leukocyte depletion

Matthias Gunzer*, Helge Riemann, Yasmin Basoglu, Anja Hillmer, Carsten Weishaupt, Sandra Balkow, Bernd Benninghoff, Beat Ernst, Meike Steinert, Thomas Scholzen, Cord Sunderkotter, and Stephan Grabbe

German Research Centre for Biotechnology, Braunschweig, Germany; Department of Dermatology, University of Munster, Munster, Germany
Department of Dermatology, University of Munster, Munster, Germany
German Research Centre for Biotechnology, Braunschweig, Germany
3M Medica GmbH, Neuss, Germany
University of Basel Institute of Molecular Pharmacy, Basel, Switzerland
Department of Dermatology, University of Munster, Munster, Germany; Department of Dermatology, University of Essen, Essen, Germany

* Corresponding author; email: mgunzer{at}gbf.de.

Toll-like receptor (TLR) ligands lead to the induction of pro-inflammatory cytokines and are potent enhancers of specific immune responses. We show here that a single systemic dose of R-848, a ligand for TLR7, potently enhanced hapten sensitization during the induction of contact hypersensitivity (CHS). However, R-848 administration also resulted in a rapid and almost complete depletion of leukocytes from the blood. This effect was transient and was associated with general induction of endothelial adhesiveness. In response to R-848 endothelial cells up-regulated adhesion molecules in vitro and in vivo and leukocytes exhibited increased rolling on endothelia in R-848 treated animals. Adhesion molecule induction appeared to be a direct effect, since endothelial cells expressed TLR7 in vitro and in vivo. After R-848 treatment, the tissue residence time of leukocytes was markedly prolonged in all major peripheral organs. The resulting transiently reduced availability of PBL (TRAP) significantly inhibited otherwise potent CHS responses until the effector cells returned. Thus, although TLR7 ligands are effective adjuvants for the induction of cell mediated immunity, they can transiently inhibit the elicitation of localized immune responses, possibly due to a systemic endothelial activation throughout the vasculature.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Baenziger, M. Heikenwalder, P. Johansen, E. Schlaepfer, U. Hofer, R. C. Miller, S. Diemand, K. Honda, T. M. Kundig, A. Aguzzi, et al.
Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology
Blood, January 8, 2009; 113(2): 377 - 388.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Oncologist, August 1, 2008; 13(8): 859 - 875.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. B. Butchi, S. Pourciau, M. Du, T. W. Morgan, and K. E. Peterson
Analysis of the Neuroinflammatory Response to TLR7 Stimulation in the Brain: Comparison of Multiple TLR7 and/or TLR8 Agonists
J. Immunol., June 1, 2008; 180(11): 7604 - 7612.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Z. Dudek, C. Yunis, L. I. Harrison, S. Kumar, R. Hawkinson, S. Cooley, J. P. Vasilakos, K. S. Gorski, and J. S. Miller
First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer
Clin. Cancer Res., December 1, 2007; 13(23): 7119 - 7125.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Reichardt, B. Dornbach, S. Rong, S. Beissert, F. Gueler, K. Loser, and M. Gunzer
Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse
Blood, September 1, 2007; 110(5): 1519 - 1529.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
L. I. Harrison, C. Astry, S. Kumar, and C. Yunis
Pharmacokinetics of 852A, an Imidazoquinoline Toll-Like Receptor 7-Specific Agonist, Following Intravenous, Subcutaneous, and Oral Administrations in Humans
J. Clin. Pharmacol., August 1, 2007; 47(8): 962 - 969.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Kamphuis, T. Junt, Z. Waibler, R. Forster, and U. Kalinke
Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia
Blood, November 15, 2006; 108(10): 3253 - 3261.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
J. Heidemann, W. Domschke, T. Kucharzik, and C. Maaser
Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense?
Infect. Immun., October 1, 2006; 74(10): 5425 - 5432.
[Full Text] [PDF]


Home page
JEMHome page
R. Chakraverty, D. Cote, J. Buchli, P. Cotter, R. Hsu, G. Zhao, T. Sachs, C. M. Pitsillides, R. Bronson, T. Means, et al.
An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues
J. Exp. Med., August 7, 2006; 203(8): 2021 - 2031.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020